Symposium on ‘Molecular basis for diseases’

ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation

A. M. Minihane1*, L. Jofre-Monseny2, E. Olano-Martin1 and G. Rimbach2

1Hugh Sinclair Unit of Human Nutrition, School of Chemistry, Food Biosciences and Pharmacy, University of Reading, Reading RG6 6AP, UK
2Institute of Human Nutrition and Food Science, Christian Albrechts University, Hermann-Rodewald-Strasse 6, 24098 Kiel, Germany

Cardiovascular risk is determined by the complex interactions between genetic and environmental factors. The apoE genotype represents the most-widely-studied single nucleotide polymorphism in relation to CVD risk, with >3600 publications cited in PubMed. Although originally described as a mediator of lipoprotein metabolism, the lipoprotein-independent functions of apoE are being increasingly recognised, with limited data available on the potential impact of genotype on these metabolic processes. Furthermore, although meta-analyses suggest that apoE4 carriers may have a 40–50% increased CVD risk, the associations reported in individual studies are highly heterogeneous and it is recognised that environmental factors such as smoking status and dietary fat composition influence genotype–phenotype associations. However, information is often derived from observational studies or small intervention trials in which retrospective genotyping of the cohort results in small group sizes in the rarer E2 and E4 subgroups. Either larger well-standardised intervention trials or smaller trials with prospective recruitment according to apoE genotype are needed to fully establish the impact of diet on genotype–CVD associations and to establish the potential of dietary strategies such as reduced total fat, saturated fat, or increased antioxidant intakes to counteract the increased CVD burden in apoE4 carriers.

ApoE genotype: CVD: Dietary fat: Oxidative status: Inflammation

The impact of single nucleotide polymorphisms on risk of chronic diseases such as CVD, and the ability of dietary factors to manipulate genotype–phenotype associations, is being increasingly recognised. Undoubtedly, the most-widely-studied gene variant in relation to CVD is the apoE ε (ε2, ε3, ε4) genotype. Since its discovery in 1973 the central role of the apoE protein in lipoprotein metabolism has been comprehensively investigated and reported. The 40–50% higher risk of CVD in apoE4 carriers (Song et al. 2004) has been traditionally attributed to moderately higher circulating cholesterol and TAG levels. However, it is becoming increasingly recognised that an effect on lipoprotein metabolism alone cannot explain the disease differential and that the impact of an apoE4 genotype is largely lipoprotein independent. Roles of macrophage-derived apoE protein on vascular health and atherogenesis are being identified, with apoE thought to impact on oxidative status and in an autocrine and paracrine manner affect macrophage, vascular smooth muscle cell, endothelial cell and platelet function. An impact of genotype on these localised functions of apoE could in part explain the impact of genotype on CVD pathology, as will be discussed.

Additionally, apoE genotype has been shown to affect the responsiveness to the total fat content and fatty acid composition of the diet. Manipulation of dietary fat content may serve as a means of reducing the increased CVD burden associated with an apoE4 genotype.

Abbreviations: HDLC, HDL-cholesterol; LDLC, LDL-cholesterol.
*Corresponding author: Dr Anne M. Minihane, fax +44 118 9310080, email a.m.minihane@reading.ac.uk
ApoE structure and tissue sources

ApoE was first described as a component of VLDL in the circulation (Shore & Shore, 1973). The full amino acid sequence was elucidated in 1982, with the mature 299 amino acid 34 kDa acid protein resulting from the proteolytic cleavage of the 317 amino acid product of the apoE gene (Rall et al. 1982). ApoE is found in the circulation associated with chylomicrons, VLDL and HDL at a typical concentration of 20–60 mg/l (Bhatnagar & Durrington, 1993).

The protein assumes a typical apo form with two structural domains (Fig. 1; from Hatters et al. 2006). The amino terminal (22 kDa) comprises residues 1–191 and ‘houses’ the lysine- and arginine-rich receptor-binding region contained between amino acids 136 and 150 (Innerarity et al. 1983). The carboxyl terminal (10 kDa) consists of residues 225–299 and contains the major lipid-binding determinants that anchor apoE to the lipoprotein (Wetterau et al. 1988). These domains are separated by a protease-sensitive hinge region (Wetterau et al. 1988). Despite the independent folding of the two domains, there are recognised domain interactions (Dong & Weisgraber, 1996).

The structure of the carboxyl-terminal domain is unknown but is predicted to be mostly α-helical (Nolte & Atkinson, 1992), whilst the three-dimensional structure of the amino-terminal domain in lipid-free solution has been determined by X-ray crystallographic studies to be an elongated globular four-helix bundle. Helix 1 pairs with helix 2, and helix 3 with helix 4, arranged in an anti-parallel mode, with the hydrophobic faces oriented towards the interior of the bundle (Wilson et al. 1991). ApoE genotype impacts on the three-dimensional orientation of the apoE regions and amino-terminal–carboxyl-terminal interactions, which affect receptor binding and lipoprotein apoE distribution, as will be discussed (see pp. 185–186). For more detailed information on apoE structure and structure–function relationships, see Hatters et al. (2006).

ApoE is synthesised mainly in the liver, with hepatocytes being the main producers. It has been estimated that between 20 and 40% of the total apoE protein is produced by extrahepatic tissues, with the brain and the monocyte-derived macrophages expressing relatively high amounts (Basu et al. 1982; Kayden et al. 1985; Newman et al. 1985; Wang-Iverson et al. 1985). ApoE is also synthesised by a range of other tissues, including steroidogenic organs such as the adrenal glands, testes and ovary (Blue et al. 1983; Polacek et al. 1992), lungs (Dawson et al. 1989), kidney (Wallis et al. 1983) and adipose tissue (Zechner et al. 1991), and in the retinal pigment epithelial cells (Ishida et al. 2004).

Role of apoE in lipoprotein metabolism

ApoE is known to play a multi-functional role in lipoprotein metabolism, potentially acting as a cofactor in VLDL synthesis, the hydrolysis of VLDL remnants to produce...

Fig. 1. Key structural elements of apo E (reprinted from Hatters et al. 2006, with permission from Elsevier). (a) The amino-terminal domain consists of a four-helix bundle that contains the LDL receptor-binding region of the protein contained between amino acids 136–150 in helix 4. Contained within the ‘hinge region’, amino acid 172 is thought to be essential for receptor binding. The carboxyl-terminal domain contains the lipoprotein-binding region. (b) The model demonstrates the impact of the replacement of Cys with Arg on position 112 in the protein. This replacement facilitates the interaction between Arg 61 and Glu 255, which mediates closer contact between the amino-terminal and carboxyl-terminal domains.
LDL and as a high-affinity ligand for the receptor-mediated cellular removal of lipoprotein remnants. Although apoE is a constituent of Golgi VLDL, there are inconsistencies in the literature in relation to the essentiality of apoE in hepatic VLDL synthesis and secretion (Schaefer et al. 1986; Fazio & Yao, 1995; Huang et al. 1999). Undoubtedly, the most important role of apoE in lipoprotein metabolism is as a high-affinity ligand for receptors of the LDL receptor family, and the impact of genotype on lipoprotein metabolism is thought to be largely the result of an effect on the receptor binding activity of apoE. Members of this family include the LDL receptor, the LDL receptor-related protein, the VLDL receptor and the apoE receptor 2 (Strickland et al. 2002).

The apoE–receptor interactions, which mediate the cellular uptake of VLDL and chylomicron remnants, have been widely studied (Bradley & Gianturco, 1986; Mahley, 1988). It is thought that the basic amino acids located between residues 136 and 150, which produce a large region of positive electrostatic potential, are important for its interaction with the acidic amino acid ligand-binding region of members of the LDL receptor family (Weisgraber, 1994). Since single amino acid substitutions in this portion of the protein result in defective binding but not in complete abolition of binding activity, it is considered that the basic amino acids cooperate in the interaction with the receptor (Wilson et al. 1991). Subtle changes around the LDL receptor-binding region also lead to defective receptor activity, as will be discussed.

ApoE receptor 2 (also termed LRP8) is structurally distinct from other family members in having a longer cytoplasmic domain. Furthermore, its pattern of tissue distribution is different from that of other receptors (Kim et al. 1996), with apoE receptor 2 lacking in the liver but found abundantly in the brain and in several other tissues such as platelets and testes (Riddell et al. 1999). It is thought that apoE receptor 2 is involved in the role of apoE in cellular signalling pathways, which is at present poorly understood. Furthermore, the precise apoE sequence that binds to this receptor has not been established (Li et al. 2003).

ApoE also binds to scavenger receptor type BI and cell glycosaminoglycans, including heparin and heparin sulphate proteoglycans. ApoE binding to heparin sulphate proteoglycans is thought to be an initial step in the localisation of apoE-containing lipoproteins to the surface of different cell types. The best understood physiological role for this interaction is the hepatic clearance of remnant lipoproteins, contributing to the initial sequestration and subsequent uptake steps, either in association with LDL receptor-related protein or acting alone (Mahley & Ji, 1999; Libeu et al. 2001).

Impact of apoE genotype on protein structure and function

In man the apoE gene is mapped to chromosome 19 in a cluster with apoC1 and apoC2. It extends for 3610 bases and consists of four exons (44, 66, 193 and 869 bp) and three introns (760, 1092 and 592 bp; Paik et al. 1985). Currently, forty-five single nucleotide polymorphisms have been identified for the apoE gene (National Center for Biotechnology Information (2006) single-nucleotide polymorphism database), twenty-seven in the intronic region and eighteen in coding regions (Table 1).

<table>
<thead>
<tr>
<th>SNP ID</th>
<th>Nucleotide change</th>
<th>Position in protein</th>
<th>Amino acid change</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs11542031</td>
<td>C/T</td>
<td>32</td>
<td>Arg</td>
</tr>
<tr>
<td>rs11542038</td>
<td>A/G</td>
<td>42</td>
<td>Thr</td>
</tr>
<tr>
<td>rs11542033</td>
<td>A/C</td>
<td>94</td>
<td>Ser</td>
</tr>
<tr>
<td>rs11542037</td>
<td>A/G</td>
<td>103</td>
<td>Arg</td>
</tr>
<tr>
<td>rs11542039</td>
<td>A/G</td>
<td>124</td>
<td>Ala</td>
</tr>
<tr>
<td>rs769452</td>
<td>T/C</td>
<td>28</td>
<td>Leu</td>
</tr>
<tr>
<td>rs11542029</td>
<td>C/T</td>
<td>32</td>
<td>Arg</td>
</tr>
<tr>
<td>rs11083750</td>
<td>A/C/G</td>
<td>84</td>
<td>Pro</td>
</tr>
<tr>
<td>rs11083750</td>
<td>A/C/G</td>
<td>84</td>
<td>Pro</td>
</tr>
<tr>
<td>rs11542040</td>
<td>A/C</td>
<td>84</td>
<td>Pro</td>
</tr>
<tr>
<td>rs429358 (e4)</td>
<td>T/C</td>
<td>112</td>
<td>Cys</td>
</tr>
<tr>
<td>rs11542041</td>
<td>A/C</td>
<td>114</td>
<td>Arg</td>
</tr>
<tr>
<td>rs11542035</td>
<td>A/G</td>
<td>119</td>
<td>Arg</td>
</tr>
<tr>
<td>rs11542034</td>
<td>A/G</td>
<td>132</td>
<td>Glu</td>
</tr>
<tr>
<td>rs769455</td>
<td>C/T</td>
<td>145</td>
<td>Arg</td>
</tr>
<tr>
<td>rs7412 (e2)</td>
<td>C/T</td>
<td>158</td>
<td>Arg</td>
</tr>
<tr>
<td>rs11542032</td>
<td>A/G</td>
<td>171</td>
<td>Glu</td>
</tr>
<tr>
<td>rs11542030</td>
<td>A/G</td>
<td>187</td>
<td>Gin</td>
</tr>
</tbody>
</table>

SNP ID, single-nucleotide polymorphism identification; N/A, not available.

A common and widely characterised genotype is the apoE-e3 missense mutations that result in three allelic isoforms e2, e3 and e4 (Table 1). The protein products differ in the amino acid present at residue 112 (rs429358) and 158 (rs7412) of the protein (Tables 1 and 2). ApoE2 contains 112 Cys/158 Cys, apoE3 112 Cys/158 Arg, and apoE4 112 Arg/158 Arg (Weisgraber et al. 1981; Rall et al. 1982). Although the amino acids alterations do not occur within the receptor binding region (amino acids 136–150), the substitutions at positions 112 and 158 are known to impact on the salt bridge formation within the protein, which ultimately impacts on the receptor binding activity and lipoprotein ‘preference’ of the apoE protein. ApoE3 and apoE4 have comparable LDL receptors affinity, but the binding of apoE2 is 50–100 times weaker (Weisgraber et al. 1982; Weisgraber, 1994). The replacement of an arginine residue with cysteine at position 158 is thought to eliminate a salt bridge between Asp154 and Arg 158 with a new bridge forming between Arg 150 and Asp 154, which dramatically alters the conformation of the receptor binding domain (Hatters et al. 2006, Fig. 1). The impact of genotype on the binding of apoE to other members of the LDL–receptor family is relatively unknown; although no substantial impact of isoform on LDL receptor-related...
protein- and VLDL receptor–apoE interactions has been observed in a series of in vitro binding studies (Ruiz et al. 2005).

The Cys112 to Arg112 substitution in apoE4, although not appearing to appreciably influence receptor binding, is thought to impact on both protein stability and carboxyl-terminal and amino-terminal domain interactions (for review, see Hatters et al. 2006). An arginine moiety at this position is thought to impact on the conformation of Arg61, allowing its interaction with an acidic Glu255 residue in the carboxyl-terminal (Fig. 1). This interaction affects the protein conformation, resulting in a ‘molten globule’ structure (Morrow et al. 2002) with a preference for larger VLDL and chylomicron remnants, in contrast to apoE2 and apoE3, which prefer smaller cholesterol-rich HDL particles. The higher lipid-binding affinity of apoE4 is not influenced by the particle size (Saito et al. 2003).

This impact on protein structure also affects molecular stability, with susceptibility of the isoforms to degradation being in the following order E4 > E3 > E2 (Acharya et al. 2002).

### ApoE allelic frequency and genotype distributions

Globally, the apoE allelic distribution shows substantial variation, with an allele frequency of 60–90% for the wild-type ε3 allele (Corbo & Scacchi, 1999; Singh et al. 2006).

The studies reviewed by Eichner et al. (2002) demonstrate that approximately 65% of Caucasian populations are homozygous ε3/ε3, 19% are ε3/ε4, 10% are ε2/ε3, 4% are ε2/ε4, 2% are ε4/ε4 and 0–5% are ε2/ε2. In Europe there is a geographic cline, with 2-fold higher prevalence of the ε4 allele in northern Europe compared with southern Europe (Corbo & Scacchi, 1999; Eichner et al. 2002; Singh et al. 2006; Table 3), which is likely to make a contribution to the north–south differences in CVD incidence observed.

### ApoE genotype and cardiovascular risk and incidence: impact of age and gender

Over the last three decades numerous studies using a variety of CHD end points, including clinically- and angiographically-defined CHD, have investigated the impact of apoE genotype on CHD risk. The main studies have been summarised in two meta-analyses (Wilson et al. 1996; Song et al. 2004). The Wilson et al. (1996) analysis summarises data from fourteen published observational studies, with carriers of the ε4 allele having an overall OR for CHD of 1·26 (95% CI 1·13, 1·41) and a non-significant OR of 0·98 (95% CI 0·85, 1·14) evident in ε2 carriers. On removing the Utermann et al. (1984) study, which demonstrated a cardio-protective effect of E4 and reported results that were clearly divergent from all other studies, an OR of 1·44 (95% CI 1·27, 1·62) was observed. This finding is in agreement with the more-recent meta-analysis (Song et al. 2004), which includes data from 15 492 CHD cases and 32 965 controls. Overall OR of 1·42 (95% CI 1·26, 1·61) and 0·98 (95% CI 0·66, 1·46) were observed for the E4 and E2 subgroups. However, findings from the forty-eight studies included are highly heterogeneous with mean OR values derived from the individual studies ranging from 0·68 to 4·35 in ε4 carriers compared with the wild-type E3/E3 genotype. Such heterogeneity is likely to be attributable to an array of factors, including environmental factors such as smoking status and background diet, and also the age and gender of the study cohort.

Currently, a comprehensive review of the impact of age and gender on apoE genotype–CHD associations is distinctly lacking. Data from the Framingham Offspring study (Wilson et al. 1994; Lahoz et al. 2001; Elosua et al. 2004) suggest a protective effect of an E2 genotype and a greater sensitivity to the deleterious effects of an E4 genotype in females compared with males. In relation to age, it appears that the impact of genotype on CVD risk is attenuated with age (Jarvik et al. 1994; Ilveskoski et al. 1999), with a lack of association of genotype with disease risk in older cohorts (Kuusisto et al. 1995). For example, in the Helsinki Sudden Death Study (Ilveskoski et al. 1999), which conducted lesion staining of the coronary arteries of 700 individuals, age x genotype interactions were observed, with an impact of genotype only present in the group who were <53 years old.

It is speculated that the apparent age-related weakening of the association may be (a) attributable to the masking effect of an overall ‘at-risk’ phenotype, which is reflected in more extensive atherogenesis, reducing the variability and the association with any one genetic factor, or (b)...

### Table 2. ApoE isoform amino acid differences and physio-chemical changes

<table>
<thead>
<tr>
<th>Isoform</th>
<th>Amino acid 112</th>
<th>Amino acid 158</th>
<th>LDL receptor binding</th>
<th>Lipoprotein preference</th>
</tr>
</thead>
<tbody>
<tr>
<td>E2</td>
<td>Cys</td>
<td>Cys</td>
<td>Low</td>
<td>HDL</td>
</tr>
<tr>
<td>E3</td>
<td>Cys</td>
<td>Arg</td>
<td>High</td>
<td>HDL</td>
</tr>
<tr>
<td>E4</td>
<td>Arg</td>
<td>Arg</td>
<td>High</td>
<td>VLDL, CM</td>
</tr>
</tbody>
</table>

CM, chylomicrons.

### Table 3. ApoE allelic distribution in select populations worldwide (derived from Singh et al. 2006)

<table>
<thead>
<tr>
<th>Country*</th>
<th>n</th>
<th>ε2</th>
<th>ε3</th>
<th>ε4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turkey</td>
<td>8366</td>
<td>0·079</td>
<td>0·860</td>
<td>0·061</td>
</tr>
<tr>
<td>Italy†</td>
<td>633</td>
<td>0·040</td>
<td>0·897</td>
<td>0·063</td>
</tr>
<tr>
<td>China</td>
<td>518</td>
<td>0·092</td>
<td>0·843</td>
<td>0·065</td>
</tr>
<tr>
<td>India</td>
<td>4450</td>
<td>0·039</td>
<td>0·887</td>
<td>0·073</td>
</tr>
<tr>
<td>Spain†</td>
<td>614</td>
<td>0·080</td>
<td>0·842</td>
<td>0·078</td>
</tr>
<tr>
<td>France†</td>
<td>1228</td>
<td>0·108</td>
<td>0·771</td>
<td>0·121</td>
</tr>
<tr>
<td>USA</td>
<td>1209</td>
<td>0·075</td>
<td>0·786</td>
<td>0·135</td>
</tr>
<tr>
<td>Germany†</td>
<td>1557</td>
<td>0·082</td>
<td>0·782</td>
<td>0·136</td>
</tr>
<tr>
<td>UK†</td>
<td>621</td>
<td>0·142</td>
<td>0·722</td>
<td>0·137</td>
</tr>
<tr>
<td>New Zealand</td>
<td>426</td>
<td>0·120</td>
<td>0·739</td>
<td>0·141</td>
</tr>
<tr>
<td>Finland†</td>
<td>1577</td>
<td>0·039</td>
<td>0·767</td>
<td>0·194</td>
</tr>
<tr>
<td>Norway†</td>
<td>798</td>
<td>0·058</td>
<td>0·744</td>
<td>0·198</td>
</tr>
<tr>
<td>Nigeria</td>
<td>781</td>
<td>0·064</td>
<td>0·684</td>
<td>0·282</td>
</tr>
</tbody>
</table>

*Listed in order of ε4 allele.
†European countries.
because individuals who are particularly sensitive to the genotype-mediated effects may have already died and are therefore not included in the analysis of older cohorts.

**ApoE genotype and physiological determinants of risk for CVD**

Traditionally, an increased CVD risk in E4 carriers has been attributable to higher circulating total cholesterol and LDL-cholesterol (LDLC) in E4 carriers. As will be discussed, the sometimes moderate and often nonsignificantly higher circulating cholesterol levels in E4 carriers are not likely to explain the 40–50% higher CVD risk observed. Furthermore, the retention of a significant impact of genotype when correction is made for recognised lipid risk markers of disease (Terry et al. 1996; Humphries et al. 2001; Lahoz et al. 2001) suggests that the effect is partly mediated by lipid-independent mechanisms.

**ApoE genotype and blood lipid levels**

**ApoE genotype and LDL-cholesterol levels**

It has been documented that apoE genotype accounts for 7% of the variance of total cholesterol in healthy Caucasian individuals (Davignon et al. 1988), and it has been suggested that an adverse cholesterol profile in E4 carriers could largely explain the increased risk of coronary events in this subgroup.

In most of the populations studied, regardless of age and health status, the e4 allele has been associated with higher LDLC and apoB concentrations relative to E2 carriers (Table 4). However, relative to E3/E3 carriers only moderate differences in cholesterol exist, with the differences often not significant. In the studies included in Table 4 LDLC concentrations for E4 and E2 carriers are on average 8.3% higher and 14.2% lower respectively than those for E3 homozygotes, with the cholesterol-lowering effect of the e2 allele known to be greater than the cholesterol-raising effect of e4 allele (Davignon et al. 1988; Hallman et al. 1991; Schaefer et al. 1994).

**How does apoE genotype modulate LDL-cholesterol levels?**

The lower plasma LDLC in E3/E2 and E2/E2 subjects has been attributed to a number of mechanisms, including increased hepatic receptor-mediated LDLC removal, lower VLDL to LDL conversion rates and decreased intestinal cholesterol absorption.

In E2 carriers defective binding of the apoE2 protein to receptors will lead to reduced hepatic VLDL and chylomicron remnant uptake, resulting in a reduced hepatic cholesterol load, which in turn will trigger up-regulation of the LDL receptor (Gregg & Brewer, 1988). Increased LDL receptor expression together with reduced receptor affinity of the apoE protein would be predicted to increase apoB100-mediated LDL removal by the LDL receptor (Howard et al. 1998). In a number of human biokinetic studies a higher fractional catabolic rate of LDL has been observed in E2 subjects (Miettinen et al. 1992; Gylling et al. 1995). In addition, e2 allele carriers have been associated with lower intestinal cholesterol absorption and higher bile acid synthesis than E3 or E4 individuals (Kesaniemi et al. 1987; Miettinen et al. 1992; Gylling et al. 1995). However, these results have been challenged by Von Bergman et al. (2003), who have reported no differences in intestinal cholesterol absorption and synthesis in E2/E2 v. E4/E4 individuals. Also, there is currently no plausible mechanism linking apoE genotype and the efficiency of cholesterol absorption.

What about the higher LDLC levels in e4 allele carriers? In most studies the differences relative to E3/E3 subjects are not significant, but there is a consistent trend towards higher total cholesterol and LDLC levels in E4 carriers. Although there are no differences in LDL-receptor binding between E4 and E3 individuals, as mentioned previously the amino acid change at position 112 influences the lipoprotein ‘preference’ of the protein, leading to a higher concentration associated with TAG-rich lipoproteins (chylomicrons and VLDL) as compared with E3 homozygotes (Gregg et al. 1986; Weisgraber, 1990). More apoE per TAG-rich lipoprotein particle would be anticipated to result in increased competition with LDL for LDL receptor-mediated clearance, which may lead to increased circulating LDLC levels (Jackson et al. 2006). In a number of biokinetic studies (Gregg et al. 1986; Demant et al. 1991; Welty et al. 2000) a lower fractional catabolic rate of LDLC-apoB100 has been reported in e4 allele carriers. In addition, an increased conversion of VLDL to LDLC-apoB100 was observed in E4 individuals. This increased synthetic rate together with the reported increased intestinal cholesterol absorption efficiency (Kesaniemi et al. 1987) could contribute to the trends towards higher LDLC levels in E4 carriers.

Regardless of the mechanism for the LDLC-modulating effects, it is evident that the average 8% higher LDLC levels alone cannot explain the disease differential in E4 carriers (Law et al. 1994). Furthermore, no consistent difference in CVD risk has been observed between E2 carriers and E3/E3 individuals despite the 10–15% lower LDLC levels, which based on predictive equations would be associated with a 20–30% lower CVD risk (Law et al. 1994). Thus, it is likely that other mechanisms in part mediate the effect of apoE genotype on CVD pathology.

**ApoE genotype and other lipid risk factors for CVD**

Inconsistent associations between apoE genotype and fasting TAG levels have been reported in the literature (Brown & Roberts, 1991; Howard et al. 1998; Bercedo-Sanz et al. 1999; Inamdar et al. 2000; Szalai et al. 2000; Tan et al. 2003), and a meta-analysis (Dallongeville et al. 1992) has concluded that E2/E2, E2/E4 E2/E3 and E3/E4 subgroups have higher fasting TAG levels than E3/E3 individuals. Higher fasting TAG levels are thought to be attributable to the limited receptor affinity of the apoE2 protein present on VLDL remnants resulting in impaired hepatic clearance of TAG-rich lipoproteins. The mechanisms that could potentially contribute to the moderate hypertriacylglycerolaemia evident in E4 carriers are currently unclear.
Table 4. The impact of apoE genotype on LDL-cholesterol levels (E2/E4 excluded if present)

<table>
<thead>
<tr>
<th>Study</th>
<th>Status</th>
<th>No. of subjects</th>
<th>Gender</th>
<th>Age (years)</th>
<th>LDL levels (mmol/l)</th>
<th>Significance of difference between groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>E2 Mean ± SD</td>
<td>E3 Mean ± SD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differences between E4 and E3 groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Srinivasan et al. (1999)</td>
<td>Healthy</td>
<td>1480</td>
<td>Both</td>
<td>5–14</td>
<td>1.9 ± 2.3</td>
<td>2.5 ± 3.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21–30 (same subjects, 16 years later)</td>
<td>2.5 ± 3.0</td>
<td>3.0 ± 3.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saito et al. (2004)</td>
<td>Diabetes</td>
<td>35</td>
<td>Both</td>
<td>61 (so 2) v. 57 (so 3)</td>
<td>3.0 ± 1.1</td>
<td>3.4 ± 0.7</td>
</tr>
<tr>
<td>Ranjith et al. (2004)</td>
<td>MI</td>
<td>191</td>
<td>N/A</td>
<td>&lt;45 years</td>
<td>n 1 ≤ 3</td>
<td>3.3 ± 0.1</td>
</tr>
<tr>
<td>Almeida et al. (2006)</td>
<td>Post-menopausal</td>
<td>285</td>
<td>Female</td>
<td>HRT + 56 (SD 6.7)</td>
<td>3.7 ± 0.9</td>
<td>3.9 ± 0.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HRT – 58 (SD 9.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheehan et al. (2000)</td>
<td>Healthy</td>
<td>100</td>
<td>Both</td>
<td>19–67</td>
<td>2.27 ± 1.0</td>
<td>2.39 ± 1.0</td>
</tr>
<tr>
<td>Yue et al. (2005)</td>
<td>FHBL</td>
<td>63</td>
<td>Both</td>
<td>N/A</td>
<td>approx 1.0</td>
<td>approx 1.0</td>
</tr>
<tr>
<td>Differences between E4 and E2 groups(no differences between E3 and E4 groups)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bercedo-Sanz et al. (1999)</td>
<td>Healthy</td>
<td>187</td>
<td>Both</td>
<td>8–10</td>
<td>2.2 ± 0.4</td>
<td>2.6 ± 0.6</td>
</tr>
<tr>
<td>Pablos-Mendez et al. (1997)</td>
<td>Healthy</td>
<td>1036</td>
<td>Both</td>
<td>&gt;65</td>
<td>2.2 ± 0.8</td>
<td>2.9 ± 1.0</td>
</tr>
<tr>
<td>Rastas et al. (2004)</td>
<td>Elderly</td>
<td>491</td>
<td>Both</td>
<td>&gt;85</td>
<td>2.7 ± 1.0</td>
<td>3.6 ± 1.1</td>
</tr>
<tr>
<td>Kuusisto et al. (1995)</td>
<td>Healthy</td>
<td>1047</td>
<td>Both</td>
<td>65–74</td>
<td>4.0 ± 0.7</td>
<td>4.5 ± 0.4</td>
</tr>
<tr>
<td>Lenzen et al. (1986)</td>
<td>MI</td>
<td>570</td>
<td>Male</td>
<td>44–63</td>
<td>3.8 ± 0.9</td>
<td>4.0 ± 1.2</td>
</tr>
<tr>
<td></td>
<td>Healthy</td>
<td>624</td>
<td>Male</td>
<td>25–52</td>
<td>2.9 ± 0.7</td>
<td>3.2 ± 0.8</td>
</tr>
<tr>
<td>Welty et al. (2000)</td>
<td>Healthy</td>
<td>18</td>
<td>Both</td>
<td>39–73</td>
<td>–</td>
<td>3.5 ± 0.7</td>
</tr>
<tr>
<td>Miliadous et al. (2005)</td>
<td>Healthy</td>
<td>200</td>
<td>Both</td>
<td>21–51</td>
<td>3.5 ± 1.3</td>
<td>3.5 ± 1.0</td>
</tr>
<tr>
<td>Kesaniemi et al. (1987)</td>
<td>Healthy</td>
<td>39</td>
<td>Male</td>
<td>35–50</td>
<td>2.6 ± 0.3</td>
<td>4.2 ± 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aguilar et al. (1999)</td>
<td>Healthy</td>
<td>142</td>
<td>Both</td>
<td>38 (so 17)</td>
<td>2.2 ± 0.4</td>
<td>2.6 ± 0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inamdar et al. (2000)</td>
<td>Healthy</td>
<td>40</td>
<td>Both</td>
<td>40–60</td>
<td>3.7 ± 0.7</td>
<td>4.1 ± 0.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diabetes</td>
<td>60</td>
<td>4.3 ± 4.3</td>
</tr>
<tr>
<td>Scuteri et al. (2005)</td>
<td>Healthy</td>
<td>306</td>
<td>Male</td>
<td>41–75</td>
<td>3.1 ± 0.8</td>
<td>3.2 ± 0.1</td>
</tr>
<tr>
<td>Sanada et al. (1998)</td>
<td>Post-menopausal</td>
<td>320</td>
<td>Female</td>
<td>40–65</td>
<td>3.2 ± 0.1</td>
<td>3.4 ± 0.1</td>
</tr>
<tr>
<td>Marques-Vidal et al. (2003)</td>
<td>Healthy + obese</td>
<td>266 (235 + 31)</td>
<td>Male</td>
<td>35–64</td>
<td>3.4 ± 0.2</td>
<td>4.0 ± 0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corella et al. (2001b)</td>
<td>Healthy</td>
<td>1014</td>
<td>Male</td>
<td>44–64</td>
<td>2.9 ± 0.9</td>
<td>3.4 ± 0.8</td>
</tr>
<tr>
<td>Framingham Offspring Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Plasma TAG levels in the postprandial state (postprandial lipaemia) are recognised to be a stronger determinant of CVD risk relative to fasting TAG levels (Zilversmit, 1979; Patsh et al. 2000). It has been shown (Weintraub et al. 1987; Dallongeville et al. 1999) that E2 carriers have a relatively delayed exaggerated chylomicon remnant clearance and exaggerated lipaemia and a homozygous E2/E2 genotype is one of the recognised causes of a type III hyperbetalipoproteinaemia phenotype. However, the majority of studies (Breninkmeijer et al. 1987; Weintraub et al. 1987; Brown & Roberts, 1991; Boerwinkle et al. 1994; Orth et al. 1996) show that only E2 homozygotes have impaired chylomicon remnant clearance, with one e3 allele largely compensating for the impaired receptor binding. As for the implication of the e4 allele in postprandial metabolism, the data published are inconsistent, with only moderate trends towards impaired metabolism observed.

Although apoE is a constituent of HDL, there are much less data available on the effect of apoE genotype on HDL-cholesterol (HDLC) than there are on LDL cholesterol levels. In general, there is a trend towards a reduction in circulating HDLC levels from an E2 genotype to an E4 genotype; some studies (Dallongeville et al. 1992; Howard et al. 1998; Dallongeville et al. 1999; Minihane et al. 2000; Tan et al. 2003) have reported effects of genotype on HDLC and apoA1 levels, while other studies (Bercedo-Sanz et al. 1999; Szalai et al. 1999; Inamdar et al. 2000; Sheehan et al. 2000) have not demonstrated an association. As fasting TAG levels are known to be an important determinant of HDL metabolism and HDLC levels, it may be predicted that lower HDLC levels may be evident in E2 and E4 carriers. This lack of TAG–HDLC response to genotype suggests that a TAG-independent mechanism may also play a role in modulating the effect of genotype on HDLC.

**ApoE genotype and responsiveness to dietary fat manipulation**

The influence of environmental factors on genotype–disease associations is being increasingly recognised. A limited number of studies have indicated that alcohol intake influences apoE–CVD associations (Corella et al. 2001a,b), but the greatest evidence exists for an impact of smoking status and dietary total fat content and fatty acid composition on the LDL cholesterol modulatory effects of the apoE genotype. Responsiveness to dietary fat manipulation is recognised to be highly variable, with genetic variability known to be partly responsible. The systematic review by Masson et al. (2003) includes studies that have examined the impact of genotype on the responsiveness of fasting lipids to dietary cholesterol (fifteen individual studies) and total fat or fatty acid composition (thirty-six individual studies; mainly manipulation of SFA, MUFA and PUFA ratios). Three of the cholesterol-manipulation studies have reported a greater circulating cholesterol response in E4 carriers. Eleven of the studies that manipulated dietary fat have demonstrated a genotype × treatment interaction, with the E4 subgroup being generally the most responsive (Masson et al. 2003). For example, in the Schaefer et al. 551
(1997) study (n 148) a National Cholesterol Education Program Step 2 diet was found to result in an overall mean reduction in LDLC levels of 19% and 16% in men and women respectively, with corresponding response ranges of +3% to –55% and +13% to –39%. In the male participants, but not in the female participants, an E4 genotype was shown to be associated with greater LDLC reductions. In the systematic review (Masson et al. 2003) the lack of significance reported in many of the studies is likely to be attributable to a lack of power to detect an inter-genotype difference in response, rather than a lack of a ‘real’ biological effect of apoE genotype. Many of the studies included cohorts of less than fifty participants and retrospective apoE genotype profiling, which often resulted in small group sizes in the rare allele groups. Of the eleven studies that reported significant impacts of apoE genotype, six included more than fifty participants, with an additional study that included forty-five participants (n 15 for E3/E3, E3/E4 and E4/E4 groups) prospectively recruiting on the basis of apoE genotype (Sarkkinen et al. 1998).

It is likely that background dietary fat composition is partly responsible for the variation in associations between apoE genotype and CVD risk and blood lipid profile reported in the literature. Furthermore, in E4 individuals with a high-fat high-cholesterol high-SFA diet dietary fat manipulation may offer a viable means of counteracting the increased CVD risk. However, before this approach can be advocated with any certainty additional adequately-powered studies are needed in order to fully elucidate the impact of apoE genotype on the heterogeneity in response to dietary total fat and SFA, MUFA and PUFA content.

Recent evidence (Minihane et al. 2000) also suggests that apoE genotype may in part predict the LDLC response to fish oil fatty acid intervention. The variability of LDLC-raising effect of EPA and DHA has been frequently reported (Harris, 1997). In a study of individuals with an atherogenic lipoprotein phenotype (Minihane et al. 2000) retrospective genotyping suggests that the LDLC-raising effects observed following supplementation with 3 g EPA+DHA/d are associated with an apoE4 genotype. Additional studies are currently underway to investigate EPA/DHA–LDLC associations.

**Lipoprotein-independent effects of the apoE protein and apoE genotype: impact on macrophage, endothelial cell, smooth muscle cell and platelet function**

As mentioned earlier, although an E4 genotype is associated with moderately-higher LDLC and TAG levels and a trend towards lower HDLC levels, these effects alone are unlikely to be responsible for the higher CVD burden, even in individuals with a high total fat and saturated fat intake. It is therefore speculated that lipid-independent mechanisms may contribute substantially to disease risk.

Monocyte-derived macrophages can produce up to 20% of the total apoE (Basu et al. 1981, 1982; Newman et al. 1985; Wang-Iverson et al. 1985). The anti-atherogenic roles of macrophage apoE have been demonstrated in apoE-null rodents (Bellosa et al. 1995; Thorngate et al. 2000). In these animals low-level tissue-specific expression of human apoE in macrophages inhibits atherogenesis without substantially influencing the plasma lipid profile.

The role of locally-secreted apoE in the artery wall is currently only partly understood, but it has been proposed to exert several biological functions (Fig. 2). Acting as a paracrine agent, macrophage-derived apoE is known to influence smooth muscle cell (Swertfeger & Hui, 2001), endothelial cell (Stannard et al. 2001), lymphocyte (Mistry et al. 1995) and platelet (Riddell et al. 1997) function. Within the macrophage itself apoE is involved in reverse cholesterol efflux from macrophages (Shimano et al. 1995) and is known to modulate the cell inflammatory response through an impact on NO and proinflammatory cytokine production (Colton et al. 2001, 2002). Although data is currently lacking, accumulating evidence suggests an
impact of apoE genotype on these metabolic processes, which may be attributable partly to differences in the antioxidant capacity of the apoE isoforms.

ApoE and platelet aggregation

Desai et al. (1989) have observed that the binding of apoE as a component of large HDL2 particles to saturable sites on platelets is associated with an inhibition of platelet aggregation. More recent studies (Riddell et al. 1997, 1999, 2001) have suggested that apoE may inhibit platelet reactivity by interacting with apoE receptor 2, which would result in an increase in cellular NO levels as a result of simulation of the NO synthase signalling cascade. The impact of apoE genotype on the anti-aggregatory effect of apoE has not been investigated.

ApoE and adhesion molecule expression

In endothelial cells the interaction of apoE with apoE receptor 2 has been proposed to activate NO synthase through an effect on 1-phosphatidylinositol 3-kinase signalling, with a resultant NO-induced inhibition of vascular cell adhesion molecule-1 induction (Stannard et al. 2001). In a cell-culture model (EAhy926) Sacre et al. (2003) have observed an isoform-specific induction of endothelial NO in the order E3>E2>E4. The impact of apoE genotype on adhesion molecule expression in vivo is unknown, although a recently-completed study (AM Minihane et al. unpublished results) indicates an effect of apoE genotype on circulating vascular cell adhesion molecule levels in human volunteers, with the relative levels (E4>E3>E2) consistent with the NO induction observed by Sacre et al. (2003).

ApoE and smooth muscle cell migration and proliferation

Smooth muscle cell migration into the intima and subsequent proliferation are considered to play an important role in atherosclerosis. ApoE has been shown to inhibit platelet-derived growth factor-directed smooth muscle cell migration by binding to LDL receptor-related protein, which activates the cAMP, protein kinase cascade (Hui & Basford, 2005). In addition, apoE inhibits cell proliferation through binding to cell surface proteoglycans, by a mechanism in which inducible NO synthase is increased (Hui & Basford, 2005). It has been demonstrated that the isoforms do not differ in terms of cell migration inhibition, since binding of lipid-free apoE to LDL receptor-related protein does not show isoform preferences (Zeleny et al. 2002). On the contrary, apoE2 and apoE3 are more efficient in inhibiting smooth muscle cell proliferation than apoE4 (Zeleny et al. 2002), which is consistent with the different binding capacity of apoE to heparin sulphate proteoglycans (Cullen et al. 1998; Hara et al. 2003).

ApoE and cellular cholesterol efflux and reverse cholesterol transport

The involvement of apoE in mediating cholesterol efflux from macrophages was first identified by Basu et al. (1982) and is now supported by several lines of evidence (Shimano et al. 1995).

ApoE seems to promote cholesterol efflux when endogenously expressed and to a lesser extent when exogenously added (Lin et al. 1999), and it has been hypothesised that the macrophage and non-macrophage apoE act via divergent mechanisms (Lin et al. 1999) that work in parallel (Dove et al. 2005). The enhancing effect can be observed in the absence of acceptors (Zhang et al. 1996) and in the presence of cholesterol acceptors such as HDL or phospholipid vesicles (Mazzone & Reardon, 1994). There is a very complex literature relating to the mechanisms by which apoE influences cholesterol efflux in macrophages, and several mechanisms have been proposed (Table 5).

The metabolism of cholesterol in macrophages has been found to differ among the three isoforms. In the absence of extracellular acceptors cholesterol-loaded monocyte-derived macrophages isolated from E4/E4 carriers are less effective in cholesterol efflux than E3/E3 cells, which are less effective than E2/E2 cells (Cullen et al. 1998). In mouse macrophages (RAW 264:7) the efficiency of cholesterol efflux is in the order E2>E3>E4, which is attributed to isoform variations in binding capacities to heparin sulphate proteoglycans. A higher binding activity of apoE4 is considered to result in higher uptake or degradation of apoE, which results in lower cholesterol efflux activity (Hara et al. 2003). This lower efficiency of cholesterol efflux in E4 individuals could make an important contribution to the higher CVD burden observed.

ApoE: NO production and inflammatory status

NO is regarded as a potent macrophage pro-inflammatory mediator. The addition of apoE has been shown to increase monocyte-derived macrophage NO production (Colton et al. 2001) by increasing the uptake of arginine (the substrate for NO production) as a result of the up-regulation of the cationic acid transporter family (Colton et al. 2001). ApoE isoform-mediated differences in monocyte-derived macrophage NO production have been observed in several models, with higher levels of NO produced by apoE4 macrophages compared with apoE3 macrophages (Colton et al. 2004).

In addition to NO, macrophages produce and secrete an array of pro-inflammatory cytokines, including a number

<table>
<thead>
<tr>
<th>Role</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracellular cholesterol transport</td>
<td>Lin et al. (1999)</td>
</tr>
<tr>
<td>Facilitate HDL₃ interaction with cell membrane and cholesterol transfer onto HDL₃</td>
<td>Mazzone &amp; Reardon (1994)</td>
</tr>
<tr>
<td>Participation in the ATP-binding cascade A₁ pathway</td>
<td>Remaley et al. (2001)</td>
</tr>
<tr>
<td>Ligand for scavenger receptor B₁</td>
<td>Chroni et al. (2005)</td>
</tr>
<tr>
<td>Stimulates lecithin:cholesterol acyltransferase</td>
<td>Zhao et al. (2005)</td>
</tr>
</tbody>
</table>
of chemokines, which impact on atherogenesis in both an autocrine and paracrine manner. Data on the impact of apoE genotype on the macrophage inflammatory response are very limited. In a recent study by Ophir et al. (2003, 2005) and Lynch et al. (2003) higher production of pro-inflammatory cytokines in the brain and serum was observed in E4 v. E3 transgenic mice following injection with lipopolysaccharide (inflammatory stimulus). The study of Lynch et al. (2003) highlights that the impact of genotype is largely attributable to a differential impact of E3 v. E4 on NF-κB signalling, which may be attributable to apoE genotype-mediated differences in oxidative status.

ApoE genotype and oxidative status

There are several lines of evidence demonstrating that apoE has antioxidant capacity (Hayek et al. 1994; Pratico et al. 1998; Aviram et al. 2000; Kitagawa et al. 2002). Miyata & Smith (1996), whilst investigating the impact of apoE genotype on Alzheimer’s disease pathology, were the first to propose allele-specific differences in the antioxidant capacities of apoE isoforms in the order E2>E3>E4, with E2 emerging in in vitro systems as having a 2-fold higher antioxidant capacity relative to E4. Subsequent in vitro studies and brain autopsy investigations of patients with Alzheimer’s disease (Jolivalt et al. 2000; Tamaoka et al. 2000) have confirmed these earlier findings.

Indirect but strong evidence for a role of apoE-mediated differences in oxidative stress being important in CVD pathology is provided by two recent prospective cardiovascular-surveillance studies, i.e. the Northwick Park Heart Study (Humphries et al. 2001) and the Framingham Offspring Study (Talmud et al. 2005). Both studies conclude that after correction for classical risk factors (including lipids) an increased risk of CVD in E4 carriers is only evident in those who smoke, which strongly indicates that an impact of genotype on oxidative status is important. The results of the Northwick Park Heart Study are presented in Table 6, with an adjusted (including for blood lipids) hazard ratio of 2.79 in E4 carriers who were smokers compared with a combined genotype non-smoking group. Although no data is currently available, based on the smoking–genotype interaction observed it may also be speculated that the impact of an E4 genotype may be more evident in individuals with a low dietary antioxidant intake.

Recent evidence (Dietrich et al. 2005; Jofre-Monseny et al. 2007) supports a role of apoE genotype in mediating oxidative status. In a mixed smoking and non-smoking group 29% higher levels of lipid peroxidation (as measured by circulating F2-isoprostane levels) were observed in individuals with a total plasma cholesterol >5.6 mmol/l (Dietrich et al. 2005). Furthermore, in a murine macrophage (RAW 264.7) cell line stably transfected with the human apoE3 and apoE4 gene it was observed that an apoE4 genotype is associated with increased membrane oxidation and NO and superoxide anion radical production (Jofre-Monseny et al. 2007).

The exact molecular mechanism by which apoE could exert its antioxidant effects and why it is isoform-dependent is not well understood. A number of possible mechanisms have been suggested, including an effect of genotype on protein folding impacting on the metal-binding domain of the protein located in the amino terminal (Miyata & Smith, 1996; Pham et al. 2005). Whatever the mechanism, it seems likely that genotype differences in oxidative status, in particular within the microenvironment of the arterial intima, are partly responsible for the higher CVD risk in E4 carriers, and that therapies targeted at reducing oxidative status and its metabolic consequences could help negate the deleterious effects of an apoE genotype.

Conclusion

Although extensively investigated, the role of the apoE protein and the impact of apoE genotype on cardiovascular health and pathology are only partly understood. It is now evident that part of the CVD burden associated with an E4 genotype is independent of an effect on lipoprotein metabolism, with an impact of genotype on oxidative status and macrophage function being increasingly recognised. Furthermore, observational and intervention trials based on retrospective genotyping of the study participants have highlighted the impact of environmental factors such as smoking status and dietary fat composition on genotype–phenotype associations. Further studies using a large-scale retrospective-genotyping approach or a smaller more-focused approach with individuals prospectively recruited on the basis of genotype are needed to establish the potential of different dietary manipulations to counteract the increased CVD risk in E4 carriers (25% of the UK population). However, it is recognised that because of the complexity and cost such an approach cannot be used to investigate all potential genotype–environment–phenotype associations. Human transgenic cells and animal models can provide a useful tool to initially screen potential dietary components of interest.

Table 6. CHD adjusted hazard ratios (HR) according to apoE genotype for men participating in the Northwick Park Heart Study* (adapted from Humphries et al. 2001)

<table>
<thead>
<tr>
<th>Group</th>
<th>HR</th>
<th>95% CI</th>
<th>Adjusted HR†</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>New smokers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>1.00</td>
<td></td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Ex-smokers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E3/E3</td>
<td>1.74</td>
<td>1.00, 2.77</td>
<td>1.49</td>
<td>0.93, 2.37</td>
</tr>
<tr>
<td>E2 carriers</td>
<td>0.48</td>
<td>0.12, 2.02</td>
<td>0.47</td>
<td>0.11, 1.94</td>
</tr>
<tr>
<td>E4 carriers</td>
<td>0.84</td>
<td>0.40, 1.75</td>
<td>0.74</td>
<td>0.35, 1.55</td>
</tr>
<tr>
<td>Smokers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E3/E3</td>
<td>1.68</td>
<td>1.01, 2.83</td>
<td>1.47</td>
<td>0.87, 2.51</td>
</tr>
<tr>
<td>E2 carriers</td>
<td>1.18</td>
<td>0.46, 3.03</td>
<td>0.85</td>
<td>0.30, 2.43</td>
</tr>
<tr>
<td>E4 carriers</td>
<td>3.17</td>
<td>1.82, 5.51</td>
<td>2.79</td>
<td>1.59, 4.91</td>
</tr>
</tbody>
</table>

*Results adjusted for the never-smokers, all genotypes combined.
†Results adjusted for clinic, age, BMI, systolic blood pressure, plasma lipids (cholesterol and TAG) and fibrinogen.
References


Bradley WA & Gianturco SH (1986) ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary. *Journal of Lipid Research* 27, 40–48.


Dietrich M, Hua Y, Block G, Olano E, Packer L, Morrow JD, Hudes M, Abdukeyum G, Rimbach G & Minihane AM (2005) Associations between apolipoprotein E genotype and...


